Shanu N Kothari1, Pamela J Lambert, Michelle A Mathiason. 1. Department of Minimally Invasive Bariatric Surgery, Gundersen Lutheran Medical Foundation, Gundersen Lutheran Health System, 1900 South Ave, La Crosse, WI 54601, USA. snkothar@gundluth.org
Abstract
INTRODUCTION: We prospectively evaluated 30-day thromboembolic and bleeding events in 2 groups of laparoscopic gastric bypass patients receiving different anticoagulation regimens. METHODS: The first cohort of patients received enoxaparin 40 mg subcutaneously preoperatively, 40 mg subcutaneously on postoperative day 0, and twice daily until discharge. The second cohort of patients received unfractionated heparin 5,000 units subcutaneously preoperatively, nothing on postoperative day 0, and 5,000 units 3 times per day until discharge. RESULTS: The incidence of deep venous thrombosis in both cohorts was 0. There was 1 pulmonary embolism in the heparin cohort (P = .999). Fourteen patients (5.9%) in the enoxaparin cohort required postoperative transfusions compared with 3 patients (1.3%) in the heparin cohort (P = .011). Four patients (1.7%) in the enoxaparin cohort required re-exploration for bleeding. CONCLUSION: Both enoxaparin and heparin are effective at preventing thromboembolic events following laparoscopic gastric bypass. Heparin is the preferred agent due to the excessive bleeding complications encountered with enoxaparin.
INTRODUCTION: We prospectively evaluated 30-day thromboembolic and bleeding events in 2 groups of laparoscopic gastric bypass patients receiving different anticoagulation regimens. METHODS: The first cohort of patients received enoxaparin 40 mg subcutaneously preoperatively, 40 mg subcutaneously on postoperative day 0, and twice daily until discharge. The second cohort of patients received unfractionated heparin 5,000 units subcutaneously preoperatively, nothing on postoperative day 0, and 5,000 units 3 times per day until discharge. RESULTS: The incidence of deep venous thrombosis in both cohorts was 0. There was 1 pulmonary embolism in the heparin cohort (P = .999). Fourteen patients (5.9%) in the enoxaparin cohort required postoperative transfusions compared with 3 patients (1.3%) in the heparin cohort (P = .011). Four patients (1.7%) in the enoxaparin cohort required re-exploration for bleeding. CONCLUSION: Both enoxaparin and heparin are effective at preventing thromboembolic events following laparoscopic gastric bypass. Heparin is the preferred agent due to the excessive bleeding complications encountered with enoxaparin.
Authors: Khashayar Vaziri; Parag Bhanot; Eric S Hungness; Mark D Morasch; Jay B Prystowsky; Alexander P Nagle Journal: Surg Endosc Date: 2009-01-28 Impact factor: 4.584
Authors: Christine Stroh; D Birk; R Flade-Kuthe; M Frenken; B Herbig; S Höhne; H Köhler; V Lange; K Ludwig; R Matkowitz; G Meyer; P Pick; Th Horbach; S Krause; L Schäfer; M Schlensak; E Shang; T Sonnenberg; M Susewind; H Voigt; R Weiner; S Wolff; A M Wolf; U Schmidt; F Meyer; H Lippert; Th Manger Journal: Obes Surg Date: 2009-05-05 Impact factor: 4.129
Authors: F Celik; F Bounif; J M Fliers; B E Kersten; F M H van Dielen; H A Cense; D P M Brandjes; B A van Wagensveld; I M C Janssen; A W J M van de Laar; V E A Gerdes Journal: Obes Surg Date: 2014-10 Impact factor: 4.129